ELN David logo blue and redELN David Logo white

Education

Meetings and Workshops

Tuesday, March 3 2026

Tuesday, March 3, 2026: 22.ELN/25.KNL Symposium

Location: Congress Center Rosengarten, Mannheim.   The Symposium will have research sessions on the various types of leukemia and interdisciplinary specialities and plenary sessions for summary reports and keynote lectures.…
See more
Blood cells in red and blue background ELN David
Monday, March 2 2026

Monday, March 2, 2026: ELN-DAVID Workshop in Mannheim, Germany

Location: Parkhotel 1901, Friedrichsplatz 2, 68165 Mannheim. Stay tuned, the program will be available soon by clicking on “see more“.
See more
Blood cells in red and blue background ELN David
Sunday, Dec 7, 2025

Sunday, Dec 7, 2025: ELN-DAVID meeting at the ELN breakfast meeting at ASH

Location: Renaissance Orlando at Seaworld, 6677 Sea Harbor Drive, Orlando, FL Check the program by clicking on “see more“.
See more
Blood cells in red and blue background ELN David
Sunday, Dec 10, 2023

ELN-DAVID meeting at the ELN breakfast meeting at ASH

Manchester Grand Hyatt, San Diego, Market Place 1, Level 4. Check the program by clicking on “See more”.
See more
Blood cells in red and blue background ELN David
2022

2022 MFC-MRD workshop by Jacqueline Cloos and Angele Kelder at UMC Amsterdam

Find the full slide deck of this interactive workshop on the role of MRD in AML and the use of MFC-MRD here
See more
October 2nd 2023

European Educational Workshop on MRD in AML and CLL

We thank our sponsors for the generous support of the workshop.
See more

Education and Training

Comprehensive Protocol to Sample and Process Bone Marrow for Assesing Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Detection of measurable residual disease (MRD) is an important prognostic biomarker for refining risk assessment and predicting relapse in acute myeloid leukemia (AML). These comprehensive guidelines and recommendations with best practices for consistent and accurate identification and detection of MRD may aid in making effective AML treatment decisions.